Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: November 21, 2025
Purpose: Submission of a presentation to the Annual General Meeting (Exhibit 99.1) and incorporation by reference into Registration Statements on Form S-8 and Form F-3.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document serves as a procedural filing to distribute meeting materials rather than a financial results report.
Material Changes
No material financial changes or operational updates are detailed within the text of this Form 6-K. The filing references the submission of an Annual General Meeting presentation, the content of which is not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, risk factors, or contingencies. It solely confirms the authorization of the report by Geoffrey P. Kempler, Chairman, and the incorporation of the AGM presentation into existing registration statements.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Presentation to Annual General Meeting) for actual financial data and strategic updates.
- Verify the status of the referenced Registration Statements (Form S-8 and Form F-3) for details on equity offerings.
- Confirm the company's continued status as a development stage enterprise and its cash burn rate from the full AGM presentation.